Company Overview
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +54.19% |
| 6 Months: | +32.61% |
| 3 Months: | +16.63% |
| 1 Month: | +7.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)42.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DNLI Denali Therapeutics Inc. R2K | 22.65 | -7.86 | $3.59B | 0.00% | -53.07% | -49.59% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | - | 641.00K | 1.65M | 1.20M | 125.68M | 4.11M | 4.10M | 13.51M | 4.67M | 3.55M | 5.81M | 9.39M | 7.92M | 22.94M | 5.29M | 42.14M | 52.48M | 184.00K | 35.14M | 294.12M | 1.27M | 0 | 0 | 0 | - | - | - | - |
| Operating Income | -21.74M | -22.57M | -22.29M | -23.54M | -25.75M | -57.38M | -37.96M | 74.72M | -42.51M | -62.76M | -50.16M | -57.76M | -59.97M | -61.28M | -60.12M | -71.22M | -61.82M | -85.59M | -66.50M | -61.42M | -107.49M | -120.81M | 170.48M | -113.80M | -117.72M | -116.59M | -123.19M | -145.58M | -134.96M | -137.43M | -137.36M |
| Net Income | -21.32M | -22.13M | -21.84M | -22.89M | -23.68M | -54.72M | -35.37M | 77.53M | -38.99M | -58.34M | -46.26M | -54.02M | -56.76M | -58.76M | -58.23M | -70.04M | -60.69M | -84.59M | -65.22M | -58.79M | -103.30M | -109.78M | 183.38M | -99.35M | -101.80M | -99.03M | -107.19M | -132.97M | -124.12M | -126.90M | -128.45M |
| Diluted EPS | - | - | - | - | -0.26 | -0.59 | -0.38 | 0.79 | - | - | - | - | -0.55 | -0.56 | -0.54 | -0.58 | -0.50 | -0.69 | -0.53 | -0.48 | -0.84 | -0.80 | 1.30 | -0.72 | -0.68 | -0.59 | -0.63 | -0.78 | -0.72 | -0.74 | -0.69 |
| R&D Expense | 18.47M | 19.00M | 18.52M | - | 20.82M | 52.13M | 30.32M | - | 37.40M | 51.88M | 52.54M | - | 51.02M | 53.15M | 53.70M | 60.21M | 65.71M | 71.56M | 86.10M | 92.74M | 87.79M | 128.82M | 97.52M | 89.74M | 107.02M | 91.40M | 98.24M | 116.23M | 102.70M | 101.95M | 103.85M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 129.10M | 26.32M | 335.56M | 48.66M | 105.06M | 330.53M | 0 | 0 |
| Operating Income | -87.43M | -90.14M | -46.37M | -213.18M | 62.72M | -295.75M | -340.74M | -196.70M | -487.34M | -555.34M |
| Net Income | -86.65M | -88.19M | -36.24M | -197.61M | 71.14M | -290.58M | -325.99M | -145.22M | -422.77M | -512.54M |
| Diluted EPS | - | - | -0.39 | -2.07 | 0.63 | -2.39 | -2.60 | -1.06 | -2.57 | -2.97 |
| R&D Expense | 75.70M | 74.46M | 143.18M | 193.38M | 212.62M | 265.35M | 358.73M | 423.88M | 396.44M | 418.78M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 486.72M | 661.98M | 553.23M | 1.60B | 1.40B | 1.46B | 1.15B | 1.37B | 1.14B |
| Total Equity | -15.63M | -94.15M | 465.80M | 546.85M | 394.89M | 1.15B | 962.29M | 1.04B | 1.03B | 1.23B | 1.01B |
| Cash & Equivalents | - | 39.85M | 218.38M | 77.12M | 79.45M | 507.14M | 293.48M | 218.04M | 127.11M | 174.96M | 205.33M |
| Total Liabilities | - | - | 20.93M | 115.14M | 158.34M | 453.75M | 441.87M | 417.81M | 122.96M | 144.50M | 131.09M |
| Current Liabilities | - | - | 14.16M | 32.79M | 45.34M | 71.70M | 378.25M | 363.92M | 77.98M | 102.21M | 98.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -71.91M | -76.64M | 50.12M | -151.58M | 416.15M | -211.39M | -244.72M | -357.99M | -347.69M | -412.60M |
| Investing Cash Flow | -219.00M | -41.17M | -287.42M | 147.71M | -623.21M | -21.63M | -141.39M | 249.31M | -88.76M | 255.28M |
| Financing Cash Flow | 300.48M | 296.32M | 97.02M | 6.19M | 634.75M | 19.35M | 310.67M | 17.82M | 484.30M | 189.22M |
| Capital Expenditure | -6.13M | -2.88M | -3.39M | -17.92M | -3.10M | -8.50M | -17.83M | -12.94M | -15.91M | -9.50M |
| Free Cash Flow | -78.04M | -79.51M | 46.72M | -169.50M | 413.06M | -219.89M | -262.55M | -370.93M | -363.61M | -422.10M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -35.9% | -810.0% | 18.7% | -607.8% | -324.3% | -59.5% | - | - |
| Net Margin % | - | - | -28.1% | -750.8% | 21.2% | -597.2% | -310.3% | -43.9% | - | - |
| ROE % | 92.0% | -18.9% | -6.6% | -50.0% | 6.2% | -30.2% | -31.3% | -14.1% | -34.4% | -50.6% |
| ROCE % | - | -19.1% | -7.4% | -42.0% | 4.1% | -28.8% | -31.1% | -18.3% | -38.3% | -53.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.21% | 13.03M | $336.94M |
| 2 | BAILLIE GIFFORD & CO | 7.60% | 12.07M | $311.92M |
| 3 | T. Rowe Price Investment Management, Inc. | 5.37% | 8.52M | $220.22M |
| 4 | Temasek Holdings (Private) Ltd | 4.42% | 7.01M | $181.29M |
| 5 | State Street Corporation | 3.95% | 6.27M | $162.13M |
| 6 | Vanguard Capital Management LLC | 3.87% | 6.15M | $158.92M |
| 7 | Vanguard Portfolio Management LLC | 3.86% | 6.12M | $158.21M |
| 8 | FMR, LLC | 2.88% | 4.58M | $118.27M |
| 9 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2.79% | 4.43M | $114.58M |
| 10 | Goldman Sachs Group Inc | 2.78% | 4.41M | $113.93M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DNLI
DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxOYWlDa1hjRXh6a1VOUDg2dEhPTFFNTUI5b3BPWF92TWlEV0MyRlhLb1hXYlk4WUlUa0duUEQ5VVNoc2VqcGpvTFpfLVhxNHoxbXNzMm40SnF3RERrWjFWSG1pY0IyRVNHSmhBUWpJV0FxcGNfdDVsM18xM2lrMTZFUUFuWnlTWEY3VnFr?o…
Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer’s - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxNUElZUjFMSHVha2xHS29XQlN2MGZsUGE0aHh6ZmNUZGtncjFTQ3JpUW9iVXJDcjhnNjE2azQ1NXAyaDBtelBWdTh0NG9yZ0lhUWdHMDJUMC1WQTZSaVVUZV9mRjNXOTRVSE9iN2lwZTE1MENzdEdyalpCSWxoVldUcW1ROWFUeDUyQU1WdU…
Denali Therapeutics (DNLI) Secures Overweight Rating from JPMorg - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQYVdqbWlGbDh5TTVlSGtKb1pFN21OUmc4SmRpNVJyWnZqT2lXaHMyaFFDa0NNUnJJSmxLX3BWZ2phNVVQMEkwY0NaTy1tNkJVZjlMaVJVMnFqSm1idDMyVi1laVdCU2xranRORDllYmJIcXVKVW52Y0tpb2Zzc1VQOG5sR0hGVDNQUHR0VT…
T. Rowe Price’s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics (DNLI) - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPUFBSYmI1RHVmenlIT1ZWNWpzb0tPSmtCZXVjQi0tZndkLXFsa3VuSk1tQnJ2TzZUQzVsUWs2aV94VW1zdDNNUjk0VjhVcTE2VWxKdWRuY1JLa3IxRkdSbnh6LVJEVTZkbnNjd3lGY2QtSldNM0syNFFudUJuMTFwSFJMYnZQQVloSFBLNC…
$DNLI stock is up 7% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQbTlRb0d1cFB2QlVwVWpka3hLTnRXdWhfeTNHR2xxdWlMWEpUNDJaeVEtLUhPY0lQQnNidGJidUpHVzRmTXBDUkRBRWZaSmM1RV80UlVBQVg0bWxBbDdreGdfcVFMdm1FQ1dZb0tnaGc2WkJfUzAxdTFHelhBdWpsWHBUeUpyc2pCU2xMV3…
DNLI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE92SVhoMVBXRUtHS2x2T2djeUlWYnM2aHNVUlRKTFJHdXpnNlAwVUtxbWVvekNWR0o2b3dYZmZUZG1sYVgyMjVMOUZCQjFhM1kzckF1c0ZNeHpNUE5qOU1vNU1CcGN5Z2EzbnhOV3BNMGI0RDk3Wlc1RnFB?oc=5" target="_blank">DNL…
DNLI — Frequently Asked Questions
What is the current share price of Denali Therapeutics Inc. (DNLI)?
As of 2026-07-14 21:23 PDT, Denali Therapeutics Inc. (DNLI) trades at $22.65 on NasdaqGS. Its 52-week range is $12.75 to $27.21.
What is the market capitalisation of DNLI?
Denali Therapeutics Inc. (DNLI) has a market capitalisation of $3.59B on NasdaqGS.
What is the P/E ratio of DNLI?
DNLI trades at a trailing price-to-earnings (P/E) ratio of -7.86. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.71.
What is the return on equity (ROE) of DNLI?
DNLI has a return on equity (ROE) of -49.59%. Its return on capital employed (ROCE) is -53.07%.
Is DNLI a good stock to buy?
This page provides a data-driven analysis of Denali Therapeutics Inc. (DNLI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.